End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.51 CNY | -1.14% | -0.18% | -10.07% |
Apr. 18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
Apr. 17 | Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.07% | 7.48B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai Fosun Pharmaceutical (Group) Gets Chinese Drug Regulator's Approval to Market COVID-19 Antigen Test Kit